CD19 and acute lymphoblastic leukemia: Data from the ZUMA-3 trial, which was conducted on adult patients with R/R B-ALL, showed a high response rate and tolerable safety of KTE-X19.Fifty-four patients were enrolled in phase 2 of the trial and forty-five of them received a single infusion of the CD19-directed product (2 × 106, 1 × 106, or 0.5 × 106 cells per kg) after lymphodepleting chemotherapy.